FindTrial
Sign In

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03424473
Enrollment
Unknown
Registered
2018-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Keywords

tucatinib, Breast Cancer, ARRY-380, ONT-380, HER2 Positive Breast Carcinoma, HER2 Positive Locally Advanced Breast Cancer, HER-2 Positive Breast Cancer, HER-2 Positive Locally Advanced Breast Cancer, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Metastatic Breast Cancer, Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Brain Metastases in Breast Cancer, Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases

Brief summary

Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).

Interventions

DRUGTucatinib

Sponsors

Seagen Inc.
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026